Ryan Allway November 18th, 2021 Psychedelics MYND Diagnostics will be initiating a clinical validation study on the use of its proprietary biomarker testing in Multiple Sclerosis diagnostics VANCOUVER, BC, Nov. 18, 2021 /CNW/ – MYND LIFE SCIENCES INC. (“MYND” or the “Company”) (CSE: MYND) (OTC: MYNDF) is pleased to announce its wholly-owned subsidiary MYND DIAGNOSTICS... Read more
MYND Diagnostics Commences Clinical Research on Alzheimer’s Disease
November 16, 2021
Ryan Allway November 16th, 2021 Psychedelics The Company will be initiating a clinical validation study on the use of its proprietary biomarker testing in Alzheimer’s Disease diagnostics VANCOUVER, BC, Nov. 16, 2021 /CNW/ – MYND LIFE SCIENCES INC. (“MYND” or the “Company”) (CSE: MYND) (OTC: MYNDF) is pleased to announce its wholly-owned subsidiary MYND DIAGNOSTICS... Read more
Ketamine Offers Promise to Veterans with PTSD
September 24, 2021
Ryan Allway September 24th, 2021 App, Exclusive, Psychedelics, Top Story Post-traumatic stress disorder, or PTSD, is a common mental illness among veterans. According to the Department of Veteran Affairs, 11% to 30% of veterans who served in foreign wars experience PTSD, far higher than the estimated 6% of the... Read more
PharmaDrug Announces Clinical Research Collaboration with The Johns Hopkins University to Evaluate DMT in a Comparative Clinical Study
August 25, 2021
Ryan Allway August 25th, 2021 Psychedelics Toronto, Ontario–(Newsfile Corp. – August 25, 2021) – PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) (“PharmaDrug” or the “Company“), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs,... Read more
Wie groß ist die psychedelische Gelegenheit?
October 29, 2020
Ryan Allway October 29th, 2020 German, Psychedelics Der nordamerikanische Markt für psychedelische Medikamente wird vorraussichtlich bis 2027 6.85 Milliarden USD erreichen, nach Daten der Data Bride Market Research, das entspricht einer jährlichen Wachstumsrate von 16.3%. Nach der Genehmigung von Johnson & Johnsons (NYSE: jnj) SPRAVATO Nasenspray für behandlusngsresistente Depressionen... Read more
